DC74470 |
SuO-Val-Cit-PAB-MMAE
|
A drug-linker conjugate for antibody-drug conjugate by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the cleavable peptide SuO-Val-Cit-PAB.. |
DC71665 |
Val-Cit-PAB-MMAF
|
Val-Cit-PAB-MMAF is a drug-linker conjugate for ADC. Val-Cit-PAB-MMAF contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin polymerization inhibitor MMAF.
|
DC71664 |
Val-Cit-PAB-MMAF sodium
|
Val-Cit-PAB-MMAF sodium is a drug-linker conjugate for ADC. Val-Cit-PAB-MMAF sodium contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin polymerization inhibitor MMAF.
|
DC71115 |
SN38 NHS ester
|
SN38 NHS ester is the NHS ester derivative of SN38. SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis. SN38 NHS ester can be used for the synthesis of antibody-drug conjugates (ADCs). |
DC48401 |
TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride
|
TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride (compound 9) is a drug-linker conjugate for ADC with potent antitumor activity by using TLR7/8 agonist 4, linked via the cleavable ADC linker hydroxy-PEG10-acid.
|
DC40875 |
MC-DM1
|
MC-DM1 is a drug-linker conjugate composed of a potent microtubule-disrupting agent DM1 and a linker MC to make antibody drug conjugate (ADC). |
DC40590 |
DBCO-PEG4-MMAF
|
DBCO-PEG4-MMAF is a drug-linker conjugate for ADC with potent antitumor activity by using the tubulin polymerization inhibitor, MMAF, linked via the cleavable linker DBCO-PEG4. |
DC40468 |
Mc-VC-PAB-SN38
|
Mc-VC-PAB-SN38 consists a cleavable ADC linker (Mc-VC-PAB) and a DNA topoisomerase I inhibitor (SN38). Mc-VC-PAB-SN38 can be used in the synthesis of antibody-drug conjugates (ADCs). |
DC11013 |
Tesirine
|
Tesirine ( SG3249) is a cathepsin B-cleavable valine-alanine pyrrolobenzodiazepine (PBD) dimer as antibody-drug conjugate (ADC) payload. |
DC8539 |
DM1-SMCC
|
DM1-SMCC is DM1 with a reactive linker SMCC, which can react with antibody to make antibody drug conjugate. |